A Phase II circulating tumor DNA enriched genomically directed post neoadjuvant trial for TNBC
Research payments
$331,108
Through program year 2025, $331,108 in research payments was reported against A Phase II circulating tumor DNA enriched genomically directed post neoadjuvant trial for TNBC, across 80 payments, paid by Genentech, Inc..
- Paid by
- Genentech, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $9,994 | 2 |
| 2024 | Research | $143,579 | 38 |
| 2023 | Research | $177,535 | 40 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Sigrun Hallmeyer Park Ridge, IL Named on 9 payments
- Erica Stringer Birmingham, AL Named on 6 payments
- Virginia Kaklamani Chicago, IL Named on 4 payments
- Peter Polewski La Crosse, WI Named on 4 payments
- Kimberly Strickland Charlotte, NC Named on 3 payments
- Rita Nanda Chicago, IL Named on 3 payments
- Dwight Owen Columbus, OH Named on 3 payments
- Nancy Davis Green Bay, WI Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.